Autopsy report · NCT01257035

Predictive Value of 18F-FAZA in Rectum Cancer

“The logistics of this trial (incl. supply of tracer) in connection with the patients' treatment course caused the inclusion rate to be very slow.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 9 months before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Vejle Hospital

Sponsor type

University, hospital or other

Conditions

Locally Advanced Rectum Cancer

Interventions

18F-FAZA-PET/CT

Participants

21

Sites

1

Countries

Denmark

Trials that died the same way

• Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
  “Due to slow inclusion of patients” (65% match in meaning)
• Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies
  “6 patients were recuited. Due to inability of the tracer to detect regions of interest sufficiently, the trial was closed early.” (64% match in meaning)
• Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)
  “Slow inclusion rate due to patients operated before intervention is implementable” (63% match in meaning)
• Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen
  “slow inclusion, due to difficulties in obtaining the patients consent for the 2 months invasive follow-up, as required by protocol design.” (59% match in meaning)
• Cetrotide Treatment Optimization
  “Due to limited rate of patient inclusion” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.